In this study, we demonstrate that IDH1-mutant AML cells are markedly more sensitive to cuproptosis induced by the copper ionophore elesclomol (ES), compared to their wild-type counterparts...In vivo experiments confirm that ES more effectively suppresses tumor growth in IDH1-mutant xenografts. These findings uncover a copper-dependent metabolic vulnerability and provide a rationale for exploiting cuproptosis as a therapeutic strategy in IDH1-mutant AML.

Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels...The synchronized delivery of Mn2+ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8+ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.

P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou

Molecular docking confirmed the robust binding affinity of CA toward pathway-associated proteins. These findings indicate CA alleviates ATO-induced myocardial injury through AMPKα2/SIRT1/PGC-1α pathway modulation, suppressing Reactive Oxygen Species, oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis.

P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

This study highlights FINs as effective cuproptosis potentiators and suggests a novel combinatorial regimen that simultaneously targets cuproptosis and ferroptosis, offering dual antitumor and bone-protective benefits for OS therapy.

P2, N=30, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

We discussed major OV platforms with respect to payload capacity, expression control, manufacturability, and clinical track records, including lessons learned from approved or late-stage OVs such as talimogene laherparepvec (T-VEC) and teserpaturev/G47Δ. Finally, we propose a pragmatic clinical workflow for rapid personalization to maximize therapeutic index. Tightly integrating neoantigen science with immunovirotherapy, including recent 2025 preclinical advances like oncolytic adenovirus neoantigen delivery sensitizing low-TMB tumors to PD-1 blockade, could enable next-generation personalized cancer vaccines capable of converting "cold" tumors into responsive, systemically controlled disease.

For the cuproptosis, Rh1 promoted the elesclomol-Cu (ES-Cu) or disulfiram-Cu induced proliferation inhibition. Finally, this work verified that Ginsenoside Rh1 promoted the cuproptosis and repressed the immune evasion of GC cells. In short, Ginsenoside Rh1 attenuated the ATP7A to potentiate the copper accumulation and cuproptosis, thereby alleviating cuproptosis-related immune evasion.

Despite prompt initiation of all-trans retinoic acid and arsenic trioxide therapy, she developed worsening respiratory distress and neurological deterioration, succumbing within 70 hours of admission...The optimal management strategies remain undefined, particularly for CNS-directed therapy. This case underscores the importance of considering extramedullary involvement in APL patients with atypical or rapidly progressive presentations.

P1/2, N=78, Active, not recruiting, AB Science | Not yet recruiting --> Active, not recruiting

P2, N=550, Completed, Synairgen Research Ltd. | Not yet recruiting --> Completed